Tango reports cancer trial success, spurring M&A
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Tango reported results from an early‑stage clinical trial in which patients with advanced pancreatic cancer experienced greater benefit from a combination of its PRMT5 inhibitor and Revolution Medicines’ pan‑RAS inhibitor than from either drug alone.
- Revolution Medicines supplied the pan‑RAS inhibitor used in the combination therapy evaluated in the Tango trial.
- STAT+ notes that no acquisition talks have been announced or even rumored between Revolution Medicines, Tango Therapeutics, or Bristol Myers Squibb.
- The article speculates possible M&A scenarios, including Revolution Medicines acquiring Tango Therapeutics or Bristol Myers Squibb acquiring Revolution Medicines.
Why it matters: Patients gain a more effective treatment option, while the trial’s positive data positions Tango and Revolution Medicines as attractive acquisition targets, reshaping market dynamics for pancreatic‑cancer therapeutics and influencing shareholder value for the firms involved and accelerate future partnership deals.
Ask SkimNews
